Audited FY2026 Results Confirm A$56.3M Loss and Going Concern Warning for Radiopharm
RADX is trading near its 52-week low of $1.43 (10% above the low).
Summary
Radiopharm's audited FY2026 annual report confirms a A$56.3M loss, A$4.14M cash balance, and a going concern warning from its auditor. The company needs to raise capital to fund operations through FY2027.
Key Events · Earnings and Guidance · RADX
-
Audited FY2026 Loss of A$56.3M
Total comprehensive loss widened 50% from A$37.9M in FY2025 to A$56.33M in FY2026, driven by a A$22.4M increase in R&D expenses to A$49.96M.
-
Going Concern Warning
Auditor Grant Thornton issued a going concern opinion, citing A$52.78M net cash outflow from operations and only A$4.14M cash as of June 30, 2026. Management expects to fund operations through FY2027 via capital raises.
-
Contingent Liabilities of A$25.77M
The company carries A$25.77M in contingent consideration liabilities across license agreements with TRIMT, Diaprost, NanoMab, Pivalate, and MD Anderson, payable upon achieving clinical milestones.
-
2.5 Billion Outstanding Options
As of June 30, 2026, there were 2,502,209,506 options outstanding with exercise prices ranging from A$0.025 to A$0.60, representing potential future dilution if exercised.
Analysis · RADX · Life Sciences
The audited 20-F confirms the FY2026 loss of A$56.33M and cash of just A$4.14M, with Grant Thornton issuing a going concern opinion. With only 0.28 quarters of cash runway, the company relies on future capital raises to continue operations. The filing also reveals A$25.77M in contingent consideration liabilities tied to clinical milestones across multiple license agreements, and 2.5 billion outstanding options that could dilute existing shareholders if exercised.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $1.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23M. The 52-week trading range was $1.43 to $16.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.